VALNEVA (EPA:VLA) | WebDisclosure

Basculer en Français

10064	Companies
205722	Keywords
135974	Articles
109074	Press releases

Home
Companies
VALNEVA

PRESS RELEASE

published on 12/04/2024 at 07:00, 1 year 3 months ago

Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal
Valneva SE announces the publication of an article on the global health and economic burden of chikungunya in The British Medical Journal, revealing higher disease burden and substantial costs

Valneva SE Global Health Chikungunya Economic Burden British Medical Journal
PRESS RELEASE

published on 12/04/2024 at 07:00, 1 year 3 months ago

Valneva annonce la publication dans le British Medical Journal d’un article sur l’impact sanitaire et économique mondial du chikungunya
Valneva SE annonce la publication d’un article sur l’impact sanitaire et économique mondial du chikungunya dans le British Medical Journal, mettant en lumière son lourd fardeau et ses coûts importants

Valneva SE Chikungunya British Medical Journal Impact Sanitaire Coûts Économiques
BRIEF

published on 11/26/2024 at 17:50, 1 year 3 months ago

Valneva Seeks FDA Approval for Chikungunya Vaccine Expansion

Valneva FDA Application Chikungunya Vaccine Adolescents Antibody Persistence
BRIEF

published on 11/26/2024 at 17:50, 1 year 3 months ago

Valneva demande l'approbation de la FDA pour l'extension de son vaccin contre le chikungunya

Valneva Adolescents Vaccin Contre Le Chikungunya Demande Auprès De La FDA Persistance Des Anticorps
PRESS RELEASE

published on 11/26/2024 at 17:45, 1 year 3 months ago

Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA
Valneva submits label extension application to U.S. FDA for its chikungunya vaccine, IXCHIQ®, to potentially include adolescents aged 12 to 17 years and two-year antibody persistence data

FDA Valneva Chikungunya Vaccine IXCHIQ Label Extension Application
BRIEF

published on 10/10/2024 at 07:05, 1 year 5 months ago

Valneva présente ses perspectives lors d'une journée investisseurs à New York

Croissance Investisseurs Valneva Vaccins Lyme
BRIEF

published on 10/10/2024 at 07:05, 1 year 5 months ago

Valneva presents its outlook at an investor day in New York

Investors Growth Valneva Vaccines Lyme
PRESS RELEASE

published on 10/10/2024 at 07:00, 1 year 5 months ago

Valneva organise une journée investisseurs aujourd’hui à New York
Valneva organise une journée investisseurs à New York pour présenter ses activités vaccinales et stratégie de création de valeur. Des présentations sur leurs principaux projets de R&D seront diffusées en direct à 16h00 CET

R&D Valneva Vaccins Journée Investisseurs Création De Valeur
PRESS RELEASE

published on 10/10/2024 at 07:00, 1 year 5 months ago

Valneva Hosts Investor Day in New York City
Valneva SE is hosting an investor day in New York City to discuss key value drivers, including Lyme disease vaccine, commercial vaccines, and R&D pipeline. Hybrid event with webcast and Q&A sessions

Investor Day Valneva SE Lyme Disease Vaccine R&D Pipeline Commercial Vaccines
BRIEF

published on 10/04/2024 at 07:35, 1 year 5 months ago

Valneva SE Announces Changes in Shares and Voting Rights

Euronext Paris Voting Rights Shares Capital Increase Valneva SE

Accesswire

Published on 03/23/2026 at 13:05, 9 minutes ago

SouthGobi Announces Disclosable and Connected Transaction Deferral of Payment Obligations Under Convertible Debenture and Amended and Restated Cooperation Agreement
Published on 03/23/2026 at 12:32, 42 minutes ago

Sinopec Announced 2025 Annual Results Annual Payout Ratio Reached 81%
Published on 03/23/2026 at 12:30, 44 minutes ago

Digi Power X to Announce 2025 Year End Financial Results on March 31st
Published on 03/23/2026 at 12:30, 44 minutes ago

High Tide Resources Announces Closing of Concurrent Non-Brokered Private Placements for Gross Proceeds of $8.3 Million
Published on 03/23/2026 at 12:20, 54 minutes ago

Guanajuato Silver Adds Veteran Mine Operator to Board of Directors

View all ACCESSWIRE

EQS Group

Published on 03/23/2026 at 13:05, 9 minutes ago

Cambrex Advances US and European Expansions
Published on 03/23/2026 at 13:02, 11 minutes ago

Directorate change
Published on 03/23/2026 at 12:40, 34 minutes ago

EQS-Adhoc: Ströer plans a dividend of €1.85 for fiscal year 2025 and approves a share buyback program of up to €50 million
Published on 03/23/2026 at 12:33, 40 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 03/23/2026 at 12:29, 45 minutes ago

Amundi Physical Metals plc: Final Terms

Les Echos

Published on 03/23/2026 at 08:10, 5 hours 4 minutes ago

Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 18 hours ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 18 hours ago

AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 18 hours ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 18 hours ago

Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA

View all LES ECHOS COMFI WIRE